Table 5.

Secondary study outcome in the 4457 patients available for primary analysis

	Major bleeding after day 90				Recurrent VTE after day 30				All‐cause mortality after day 30
	Adjusted OR per point increase (95% CI)	c‐statistic (95% CI)	Crude HR ≥2 points (95% CI)	Adjusted HR ≥2 points (95% CI)	Adjusted OR per point increase (95% CI)	c‐statistic (95% CI)	Crude HR ≥2 points (95% CI)	Adjusted HR ≥2 points (95% CI)	Adjusted OR per point increase (95% CI)	c‐statistic (95% CI)	Crude HR ≥2 points (95% CI)	Adjusted HR ≥2 points (95% CI)
All patients	1·4 (1·1–1·7)	0·71 (0·61–0·82)	3·8 (1·6–9·3)	3·2 (1·3–7·7)	1·2 (1·0–1·4)	0·60 (0·52–0·68)	1·7 (1·0–3·1)	1·5 (0·9–2·7)	2·1 (1·8–2·5)	0·88 (0·84–0·91)	14 (6·3–30)	11 (4·8–23)
Patients with unprovoked VTE	1·5 (1·1–2·0)	0·71 (0·58–0·84)	3·2 (1·1–9·5)	2·9 (1·0–8·7)	1·2 (1·0–1·5)	0·60 (0·49–0·70)	1·7 (0·8–3·5)	1·5 (0·7–3·2)	2·1 (1·7–2·5)	0·86 (0·81–0·92)	13 (4·4–39)	10 (3·4–30)

c‐statistic is based on unadjusted model.

95% CI, 95% confidence interval; HR, hazard ratio; OR, odds ratio; VTE, venous thromboembolism.